Recombinant humanized anti-ST2 monoclonal antibody
- Generic Name
- Recombinant humanized anti-ST2 monoclonal antibody
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Phase 1
Active, not recruiting
- Conditions
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06175351
- Locations
- 🇨🇳
Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath